WEBINAR: How to set yourself up for success with organ-on-a-chip

Available to watch on-demand now

cnb937 ooc success webinar promo bar v1 |
Watch webinar
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment

      • OBN Awards 2023 winner!

      • CN Bio appoints Neil Rumbelow as Director of Product Development

      View all news

      Upcoming Events

      Check back soon for upcoming events

      View all events

      Join the team!

      • Director of Sales – Americas Region

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients

December 15, 2020

CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung disease, often occurring following SARS-CoV-2 infection. Subsequently, the University will investigate anti-inflammatory, anti-fibrotic and anti-viral agents to treat patients.

For patients suffering from the chronic complications of COVID-19, many long-term health effects have been identified, including respiratory complications resulting from interstitial lung disease. Through the collaboration, CN Bio’s Sydney-based distributor, AXT, will provide the University of Melbourne access to the Company’s proprietary PhysioMimix™ Organ-on-Chip system, to create a more human-relevant COVID-infected lung culture than current in vitro standards that use monkey fibroblasts. Led by Professor Alastair Stewart, the research team will adopt the lung model to elicit physiologically comparable inflammation and cytokine responses following drug testing; to support development of novel therapies, aiming to prevent a second wave of late mortalities associated with the medium-term morbidity.

To further improve translatability of the COVID-19 infected lung culture, CN Bio’s technology will enable researchers to create an organotypic air-liquid interface, which has more utility than the organoid approach, in which cilia within the structure make it difficult to study viral infection. Additionally, viable cell culture time is predicted to be prolonged (currently 1 week), allowing for an extended study of infection and pharmacology drug intervention.

“The COVID-19 pandemic has affected everyone’s lives; we are honoured to apply our Organ-on-a-Chip capabilities to support this invaluable research addressing its ongoing complications. Selection for this project by the University of Melbourne, one of the world’s top research institutions, is a privilege for our team.” commented Dr Audrey Dubourg, Product Manager, CN Bio. “We look forward to working with Professor Alastair Stewart and his group, who will be supported by our Australian distributor, AXT, leading experts in high-tech scientific equipment.”

Professor Alastair Stewart, Director of the ARC Centre for Personalised Therapeutics Technologies, University of Melbourne, said: “If we are to avert a second wave of late mortality caused by this pandemic, research into drugs that can treat interstitial lung disease in COVID-recovered patients is crucial. Harnessing CN Bio’s microphysiological technology, we hope to enhance our understanding of the molecular mechanisms and pharmacological effects of drugs capable of treating patients that suffer with the respiratory complications.”

 For more information about CN Bio’s Organ-on-a-Chip technology, visit: https://cn-bio.com/organ-on-chip/

Category iconPress releases

Primary Sidebar

Other recent news

  • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment December 4, 2023
  • OBN Awards 2023 winner! November 23, 2023
  • CN Bio appoints Neil Rumbelow as Director of Product Development November 2, 2023
  • CN Bio showcased in PwC UK’s ‘Life Sciences Future 50’ report 2023 October 19, 2023
  • Taking organoids to the next level October 5, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment December 4, 2023
  • OBN Awards 2023 winner! November 23, 2023
  • CN Bio appoints Neil Rumbelow as Director of Product Development November 2, 2023

Upcoming events